▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #292 by analyst upside · 2026-09-16
NAUT
Nautilus Biotechnology, Inc.
Healthcare · Market Cap $113M · P/E 0x
ANALYST PRICE TARGET
+348.9%
implied upside to consensus target
Current Price $0.89
Consensus Target $4.0
Bull Target $4.0
Bear Target $4.0
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $0.68
52-Week High $4.31
YTD Return -53.4%
FUNDAMENTALS
Market Cap $113M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.44
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.68
52-Week High $4.31
Current Price $0.89
Bear Target $4.0
Bull Target $4.0
● Now $0.89 ● Target $4.0
TRADING DATA
Avg Volume 1.0M
YTD Return -53.4%
Analyst Count 2
Consensus Buy
Upside to Target +348.9%
Last Updated 2026-09-16

ANALYST SUMMARY

Nautilus Biotechnology, Inc. (NAUT) is currently trading at $0.89 with a Wall Street consensus price target of $4.0, implying potential upside of 348.9% over the next 12 months. 2 analysts currently cover NAUT, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $4.0, while the most cautious has a target of $4.0.

NAUT operates in the Healthcare sector with a market capitalisation of $113M. The stock is down 53.4% year-to-date and is currently trading near the lower end of its 52-week range of $0.68 – $4.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

FBIO +341.8%
Fortress Biotech, Inc.
$83M · P/E 0.9x · Buy
SPRO +342.5%
Spero Therapeutics, Inc.
$66M · P/E 8.1x · Buy
PLX +313.5%
Protalix BioTherapeutics, Inc.
$214M · P/E 11.6x · Buy
PALI +407.3%
Palisade Bio, Inc.
$351M · P/E 3.1x · Buy
QTTB +267.1%
Q32 Bio Inc.
$333M · P/E 3.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for NAUT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ● Initiated
Outperform 2026-09-09 29% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-02-27 62% win rate (8 calls)
Goldman Sachs ↓ Downgrade
Neutral → Sell 2024-12-05 Building track record
Guggenheim ● Initiated
Buy 2024-06-27 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
8/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →